Sangamo Therapeutics (SGMOQ) Net Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly Net Margin of 263.0% for Q4 2025, up 9694.0% year-over-year from 2.69% in Q4 2024, and up 95.63% quarter-over-quarter from 6012.05% in Q3 2025.
Sangamo Therapeutics (SGMOQ) Net Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics' Net Margin history runs 16 years deep, the most recent figure standing at 263.0% for Q4 2025.
- In Q4 2025, Net Margin rose 9694.0% year-over-year to 263.0%; the TTM figure through Dec 2025 stood at 310.81% (down 13596.0% YoY), while the FY2025 annual figure was 310.81%, down 14136.0% from the prior year.
- Net Margin for Q4 2025 stood at 263.0%, up from 6012.05% in the prior quarter.
- The five-year high for Net Margin was 18.99% in Q3 2024, with the low at 10205.61% in Q1 2024.
- The 5-year median for Net Margin is 195.82% (2022), against an average of 1730.84%.
- The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 1021899 bps in 2024, then soared 1003914 bps in 2025.
- Sangamo Therapeutics' Net Margin stood at 133.98% in 2021, then tumbled by 42 bps to 190.76% in 2022, then tumbled by 1448 bps to 2952.74% in 2023, then soared by 88 bps to 359.94% in 2024, then rose by 27 bps to 263.0% in 2025.
- Business Quant data shows SGMOQ's Net Margin at 263.0% in Q4 2025, 6012.05% in Q3 2025, and 109.18% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -263.00% |
| Sep 30, 2025 | -6,012.05% |
| Jun 30, 2025 | -109.18% |
| Mar 31, 2025 | -475.33% |
| Dec 31, 2024 | -359.94% |
| Sep 30, 2024 | 18.99% |
| Jun 30, 2024 | -10,148.31% |
| Mar 31, 2024 | -10,205.61% |
| Dec 31, 2023 | -2,952.74% |
| Sep 30, 2023 | -1,108.35% |
| Jun 30, 2023 | -1,675.29% |
| Mar 31, 2023 | 13.38% |
| Dec 31, 2022 | -190.76% |
| Sep 30, 2022 | -200.89% |
| Jun 30, 2022 | -146.96% |
| Mar 31, 2022 | -155.78% |
| Dec 31, 2021 | -133.98% |
| Sep 30, 2021 | -166.96% |
| Jun 30, 2021 | -169.23% |
| Mar 31, 2021 | -174.81% |